These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 16129526

  • 21. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine.
    Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K, Hayden FG, Bernstein DI, Kotloff K, King J, Piedra PA, Block SL, Yan L, Wolff M.
    J Infect Dis; 2000 Mar; 181(3):1133-7. PubMed ID: 10720541
    [Abstract] [Full Text] [Related]

  • 22. Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.
    Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T, Hasegawa H.
    J Virol; 2005 Mar; 79(5):2910-9. PubMed ID: 15709010
    [Abstract] [Full Text] [Related]

  • 23. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults.
    Keitel WA, Cate TR, Nino D, Huggins LL, Six HR, Quarles JM, Couch RB.
    J Infect Dis; 2001 Jan 15; 183(2):329-332. PubMed ID: 11110645
    [Abstract] [Full Text] [Related]

  • 24. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H, Ichinohe T, Strong P, Watanabe I, Ito S, Tamura S, Takahashi H, Sawa H, Chiba J, Kurata T, Sata T.
    J Med Virol; 2005 Jan 15; 75(1):130-6. PubMed ID: 15543590
    [Abstract] [Full Text] [Related]

  • 25. Antibody response after a single dose of an AS03-adjuvanted split-virion influenza A (H1N1) vaccine in heart transplant recipients.
    Meyer S, Adam M, Schweiger B, Ilchmann C, Eulenburg C, Sattinger E, Runte H, Schlüter M, Deuse T, Reichenspurner H, Costard-Jäckle A.
    Transplantation; 2011 May 15; 91(9):1031-5. PubMed ID: 21358365
    [Abstract] [Full Text] [Related]

  • 26. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.
    Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R.
    Virus Res; 2004 Jul 15; 103(1-2):163-71. PubMed ID: 15163505
    [Abstract] [Full Text] [Related]

  • 27. Mucosal antibody response induced with a nasal virosome-based influenza vaccine.
    Durrer P, Glück U, Spyr C, Lang AB, Zurbriggen R, Herzog C, Glück R.
    Vaccine; 2003 Oct 01; 21(27-30):4328-34. PubMed ID: 14505915
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.
    Lambkin-Williams R, Gelder C, Broughton R, Mallett CP, Gilbert AS, Mann A, He D, Oxford JS, Burt D.
    PLoS One; 2016 Oct 01; 11(12):e0163089. PubMed ID: 28005959
    [Abstract] [Full Text] [Related]

  • 31. AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age.
    Roman F, Vaman T, Kafeja F, Hanon E, Van Damme P.
    Clin Infect Dis; 2010 Sep 15; 51(6):668-77. PubMed ID: 20687838
    [Abstract] [Full Text] [Related]

  • 32. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
    Muhamed G, Greenbaum E, Zakay-Rones Z.
    Isr Med Assoc J; 2006 Mar 15; 8(3):155-8. PubMed ID: 16599048
    [Abstract] [Full Text] [Related]

  • 33. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W.
    Vaccine; 2008 Dec 02; 26(51):6555-63. PubMed ID: 18848856
    [Abstract] [Full Text] [Related]

  • 34. Safety, reactogenicity and immunogenicity of an intranasal seasonal influenza vaccine adjuvanted with gram-positive matrix (GEM) particles (FluGEM): A randomized, double-blind, controlled, ascending dose study in healthy adults and elderly.
    van der Plas JL, Haijema BJ, Leenhouts K, Paul Zoeteweij J, Burggraaf J, Kamerling IMC.
    Vaccine; 2024 Sep 17; 42(22):125836. PubMed ID: 38772837
    [Abstract] [Full Text] [Related]

  • 35. Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais.
    Phonrat B, Pitisuttithum P, Chamnanchanunt S, Puthavathana P, Ngaosuwankul N, Louisirirotchanakul S, Dhitavat J, Thirapakpoomanunt S, Chokevivat V, Wibulpolprasert S.
    Vaccine; 2013 Mar 01; 31(11):1503-9. PubMed ID: 23318149
    [Abstract] [Full Text] [Related]

  • 36. Phase I, randomized, controlled trial to study the reactogenicity and immunogenicity of a nasal, inactivated trivalent influenza virus vaccine in healthy adults.
    Halperin SA, Smith B, Clarke K, Treanor J, Mabrouk T, Germain M.
    Hum Vaccin; 2005 Mar 01; 1(1):37-42. PubMed ID: 17038827
    [Abstract] [Full Text] [Related]

  • 37. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
    Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M.
    Vaccine; 2009 Oct 23; 27(45):6291-5. PubMed ID: 19840662
    [Abstract] [Full Text] [Related]

  • 38. Strong local and systemic protective immunity induced in the ferret model by an intranasal virosome-formulated influenza subunit vaccine.
    Lambkin R, Oxford JS, Bossuyt S, Mann A, Metcalfe IC, Herzog C, Viret JF, Glück R.
    Vaccine; 2004 Oct 22; 22(31-32):4390-6. PubMed ID: 15474733
    [Abstract] [Full Text] [Related]

  • 39. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
    Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB.
    Clin Infect Dis; 2006 Nov 01; 43(9):1135-42. PubMed ID: 17029131
    [Abstract] [Full Text] [Related]

  • 40. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older.
    Kerzner B, Murray AV, Cheng E, Ifle R, Harvey PR, Tomlinson M, Barben JL, Rarrick K, Stek JE, Chung MO, Schödel FP, Wang WW, Xu J, Chan IS, Silber JL, Schlienger K.
    J Am Geriatr Soc; 2007 Oct 01; 55(10):1499-507. PubMed ID: 17908055
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.